Form 4: Quest Diagnostics Executive Kuppusamy Karthik Reports Stock Transactions
SEC Form 4 Filing
Karthik Kuppusamy, SVP of Clinical Solutions at Quest Diagnostics, reports the acquisition of common stock through dividend reinvestment and holdings in a 401(k) plan.
Summary
- On April 21, 2025, Karthik Kuppusamy, SVP of Clinical Solutions at Quest Diagnostics, reported transactions involving Quest Diagnostics common stock.
- He acquired 27 shares of common stock through a dividend reinvestment plan at a price of $164.422 per share.
- Kuppusamy also indirectly owns 358 shares through a trust and 1,620 shares through the company's 401(k) plan.
- Following these transactions, Kuppusamy directly owns 10,612 shares of Quest Diagnostics common stock.
Sentiment
Score: 5
Explanation: The document is a neutral report of stock transactions, with no inherent positive or negative sentiment.
Positives
- The reporting person increased their holdings in the company.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is common practice for publicly traded companies.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership.
Key Dates
| Date | Description |
|---|---|
| 04/21/2025 | Date of common stock acquisition through dividend reinvestment. |
| 05/02/2025 | Date of signature on the Form 4 filing. |
Keywords
Quest Diagnostics, Karthik Kuppusamy, stock transactions, Form 4, dividend reinvestment, 401(k), beneficial ownership, DGX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.